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 36 Genome wide association studies of gene expression traits and other cellular 37 phenotypes have been successful in revealing links between genetic variation 38 and biological processes. The majority of discoveries have uncovered cis eQTL 39 effects via mass univariate testing of SNPs against gene expression in single 40 tissues. We present a Bayesian method for multi-tissue experiments focusing on 41 uncovering gene networks linked to genetic variation. Our method decomposes 42 the 3D array (or tensor) of gene expression measurements into a set of latent 43 components. We identify sparse gene networks, which can then be tested for 44 association against genetic variation genome-wide. We apply our method to a 45 dataset of 845 individuals from the TwinsUK cohort with gene expression 46 measured via RNA sequencing in adipose, LCLs and skin. We uncover several 47 gene networks with a genetic basis and clear biological and statistical 48 significance.  Extensions of this approach will allow integration of multi-omic, 49 environmental and phenotypic datasets. 50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65  66 
Introduction 67 
 68 Studies of cellular phenotypes are transforming our understanding of the genetic 69 influences on complex traits. Genomic screens of gene expression levels1, 70 chromatin accessibility2, chromatin state3 and protein levels4 are all helping to 71 elucidate how genetics is related to disease mechanisms. Over the last few years 72 eQTL mapping has emerged as a key component in this research and has led to 73 the identification of many genetic variants affecting gene expression. Typically, 74 these studies involve assaying gene expression in a single tissue or cell type, 75 though multi-tissue experiments are beginning to emerge as a way to uncover 76 the principles of gene regulation. 77  78 The standard paradigm for single tissue eQTL studies involves testing the 79 expression of each gene or transcript against SNP genotypes in a local region to 80 identify cis eQTLs.  This approach has been successful, with recent large eQTL 81 studies suggesting that there will be at least one cis eQTL for almost all 82 expressed genes5. Multi-tissue approaches can increase the power to find cis 83 eQTLs6, however, as cis eQTLs are estimated to account for only 30-40% of the 84 heritability of expression levels7,8 there is a need to identify trans eQTLs to 85 account for the remaining heritability.  86 The detection of trans eQTLs and networks of genes with related expression 87 patterns is hard both computationally and statistically. Testing all genes against 88 all SNPs via tens of thousands of genome-wide scans incurs a substantial penalty 89 for multiple testing. In addition, trans eQTL effect sizes tend to be smaller than 90 
cis eQTLs making their detection harder9. For these reasons, scans for trans 91 eQTLs usually work with a reduced set of genetic variants, such as those 92 associated with disease traits9,10. In general, the approach of carrying out very 93 large numbers of marginal statistical tests (of one SNP versus one gene at a time) 94 ignores the complex structure of these datasets. The expression levels of each 95 gene will likely be due to a mixture of several different sources, related to 96 underlying biology and also confounding factors.  97  98 
In this paper we present a novel method for the analysis of multi-tissue gene 99 expression experiments, with a specific focus on identifying trans eQTLs and 100 gene networks. The data from such experiments can be viewed as a ‘3D’ array, or 101 tensor, with dimensions representing individual, gene and tissue (see Figure 1). 102 Our method decomposes this tensor into a number of latent components (or 103 factors) that represent major modes of variation in the dataset. Each of these 104 components consists of three vectors of scores (or loadings) that indicate the 105 relative contribution of each individual, gene and tissue. For example, if a 106 consistent pattern of gene expression across a network of genes occurs in a 107 subset of tissues, with a different magnitude in each individual, then our model 108 aims to represent this in a single component. Such signals might naturally arise 109 due to transcription factor genes that have multiple targets throughout the 110 genome. If the expression level or function of a gene is altered by cis-acting 111 genetic variants, then we would likely observe different magnitudes of effects 112 across individuals.  113  114 One useful way to think about the approach is as analogous to the use of 115 principal components analysis (PCA) applied to ‘2D’ (individual by SNP) genetic 116 datasets. PCA is routinely used to decompose genome-wide SNP datasets into 117 components of variation that are then used to understand population structure 118 (see 11 for example). Here we aim to decompose higher dimensional datasets into 119 components that uncover real biology.  120  121 Our method has several notable properties: 122 
• Our approach is developed in a Bayesian framework, and we use a sparse 123 ‘spike and slab’12 prior to allow the gene loadings of each component to 124 have a unique level of sparsity. This allows us to shrink gene effects to 125 zero so that we can infer more clearly which genes are involved in gene 126 networks.  127 
• The individual scores represent the magnitude of the effect of each 128 component across individuals, analogously to the individual scores that 129 are usually plotted in a PCA analysis of genetic datasets. We use these 130 scores as phenotypes in genome-wide SNP scans to identify genetic 131 
variants that drive each component. The number of components we test is 132 typically much smaller (a few hundred) than the number of genes (tens of 133 thousands), which substantially reduces the multiple testing burden 134 when compared to approaches that test all genes against all genetic 135 variants in all tissues. 136 
• We do not claim that all genes identified in a network will reach genome-137 wide significance thresholds with the driving SNPs. However, when 138 applied to real datasets we find that the majority of genes are nominally 139 significant. 140 
• The tissue scores vector indicates the ‘activity’ of the component for each 141 tissue. By examining the entries of the tissue scores matrix across 142 components we can make inferences about how many components are 143 shared across tissues. 144 
• Our model also allows for non-sparse components that might be expected 145 to arise from confounding effects, such as batch effects or sequencing 146 properties.  147 
• In addition, the model can naturally accommodate missing data, such as 148 samples without gene expression on subsets of tissues, which is a real and 149 prevalent feature of multi-tissue experiments. 150  151 Our motivation for this work stemmed from similar approaches that have 152 emerged in the field of neuroscience to uncover shared signals across different 153 high-dimensional imaging modalities13,14. Most tensor decomposition methods15-154 17 are not able to handle missing data or invoke sparsity on the components, 155 although there are some exceptions18. Our model is the first tensor 156 decomposition method utilizing spike and slab priors with model fitting carried 157 out using Variational Bayes (see Online Methods). Via extensive simulations 158 (Supplementary Note) we show that our method has the best performance in 159 terms of estimation of the component individual scores and recovery of sparsity 160 patterns in the gene loadings when compared to other matrix and tensor 161 decomposition methods, and is well powered to detect trans eQTL signals and 162 gene networks. Our method is implemented in a software package called SDA 163 (Sparse Decomposition of Arrays) (see URLs). 164 
 165 
Results  166  167 We have validated our approach by applying it to RNA sequencing data from the 168 TwinsUK cohort, which consists of gene expression measured on 845 related 169 individuals in adipose, LCLs and skin19,20. In order to focus on robustly identified 170 components we applied our method 10 times to the TwinsUK RNA-seq dataset 171 and combined results across runs via clustering (see Online Methods). After 172 clustering, we identified 236 robust components for further investigation. 173 Examination of the tissue scores matrix is informative about which tissues each 174 component is active in (see Supplementary Figure 1). We found that the 175 majority of the 236 components were active in a single tissue (57 in Adipose, 74 176 in LCLs and 70 in Skin). There were 20 components that were active in all 3 177 tissues, 14 components active in just Adipose and Skin and 1 component active 178 in Adipose and LCLs. The full details of these 236 components are given in the 179 
Supplementary Data Set. 180 
 181 The individual scores vectors of these components were then used as 182 phenotypes in genome-wide scans using SNP genotype data imputed using the 183 1000 Genomes Phase 1 reference panel. We used a threshold of 1×10-10 to assign 184 significance (see Online Methods). There were 26 components that reached this 185 level of significance: 5 were active in just 1 tissue (1 in Adipose, 4 in LCLs), 20 186 components were active in all 3 tissues and 1 component was active in just 187 Adipose and Skin. The majority of these components were clearly uncovering cis 188 eQTLs. In all but two of these components we identified pairs of SNPs 189 (significantly associated with our component scores) and genes (with a non-zero 190 loading) that had previously been identified as a cis eQTLs in the MuTHER and 191 GTEx studies7,21. These components exhibited very sparse gene loadings, with a 192 single localized cluster of high gene loadings and highly significant SNP 193 associations in the flanking region (Supplementary Figures 2-21). 194 Methodology for the detection of cis eQTLs is well established and is best carried 195 out using focused analysis that looks for such effects at SNPs flanking each gene. 196 
Our main focus is on uncovering trans eQTLs and gene networks so we do not 197 pursue the cis eQTLs that our method finds any further. 198  199 The remaining 6 components were less sparse in their gene loadings, and 200 exhibited patterns of gene loadings and SNP associations that highlight gene 201 expression networks with substantial biological significance. For these networks 202 the majority of gene loadings tend to be unidirectional suggesting the 203 components are identifying a directional effect on expression. These components 204 are summarized in Figures 2-6 which show the gene loadings, SNP GWAS and 205 tissue activation patterns. Supplementary Table 1 shows that the majority of 206 genes identified in each of these networks have nominally significant p-values in 207 the relevant tissues. At the suggestion of a reviewer, we also applied PCA and ICA 208 to the Twins UK dataset. Neither of these approaches uncovered the gene 209 networks reported here; more details are given in the Supplementary Note. 210  211 We found 2 clustered components (Figure 2) with individual scores that exhibit 212 significant SNP associations in the gene CIITA on chromosome 16p13 (see also 213 
Supplementary Figure 22). The first component is active mostly in Adipose and 214 Skin and has a lead SNP rs9924520 (p-value = 1.33×10-23, MAF=0.247) that is an 215 intronic variant of CIITA. The second component is active mostly in LCLs and has 216 a lead SNP rs7194862 (p-value = 1.74×10-14, MAF=0.282) that is 5’ of CIITA. The 217 SNPs rs9924520 and rs7194862 are in strong LD (r2 = 0.82). Both components 218 show a cluster of MHC Class II genes on chromosome 6 with non-zero gene 219 loadings. In addition, 2 other genes have significant gene loadings in both 220 components (RFX5 on chromosome 1 and CD74 on chromosome 5). CIITA is 221 known to be a master controller in the regulation of MHC Class II gene 222 expression22. It is recruited to the proximal promoter regions of the classical 223 MHC class II genes (HLA-DP, HLA-DR and HLA-DQ), and to HLA-DM, HLA-DO and 224 the CD74 gene (encoding the molecular chaperone invariant chain which 225 associates with the MHC class II complex) through protein-protein interactions 226 with other components of the MHC class II enhanceosome, which includes RFX5.  227 
Supplementary Table 2 details the direct associations of SNPs rs9924520 and 228 rs7194862 with the expression levels of all the genes identified in our 229 
components (in all three tissues) after correction for covariates and 15 PEER 230 factors23 (see Online Methods). Both SNPs are strongly associated with HLA-231 
DOA and HLA-DMA in Adipose and Skin (p-values in the range [2.89×10-8, 232 5.56×10-19]) and with CIITA in Adipose (p-values = 2.08×10-11, 1.44×10-12). 233 However, neither SNP reaches a strict Bonferroni threshold for a trans analysis 234 of 9.05×10-13 = 5×10-8/(3×18409) (obtained by accounting for genome-wide 235 testing across all genes in all tissues) with any of the other genes in the 3 tissues. 236 These results suggest that while a trans eQTL association would have been found 237 between SNPs in the CIITA region and expression at two MHC class II genes, the 238 more extensive network of genes recovered by our components would not have 239 been uncovered via a marginal trans analysis.  240 
 241 
Figure 3 shows significant associations in the gene NLRC5/CITA on chromosome 242 16q13 (see also Supplementary Figure 23). The lead SNP rs289749 (p-value = 243 1.34×10-11, MAF=0.3) is an intronic variant of NLRC5/CITA. The component 244 shows a cluster of genes on chromosome 6 with non-zero gene loadings that 245 include MHC Class I genes (HLA-O, HLA-B, HLA-F, HLA-A, HLA-E), BTN genes 246 (BTN3A2, BTN3A1, BTN3A3, BTN2A2, BTN2A1), TAP1, TAP2, PSMB8 and 247 
PSMB9.  Overexpression of NLRC5/CITA is known to increase mRNA levels of 248 genes encoding human MHC Class I molecules and proteins functioning in the 249 MHC Class I mediated antigen presentation pathway, including beta-2-250 microglobulin (B2M), transporter associated with antigen processing 1 (TAP1) 251 and the proteasome subunit beta type-9 (PSMB9)24. B2M, TAP1 and PSMB9 all 252 have significant gene loadings in the component. Supplementary Table 3 253 details the direct associations of SNP rs289749 with the expression levels of all 254 the genes in the component in all three tissues. In skin, rs289749 is strongly 255 associated with NLRC5/CITA (p-value = 1.37×10-28) and moderately associated 256 with several MHC class I genes; HLA-F (p-value = 3.02×10-12), HLA-A (p-value = 257 1.22×10-9) an HLA-B (p-value 1.35×10-10)); although none of these associations 258 would pass a Bonferroni corrected significance level in a trans analysis (9.05×10-259 13). p-values for association between rs289749 and other genes in this 260 component suggest that the link between NLRC5/CITA and BTN, TAP and PSMB 261 genes or the B2M gene would not have been recovered using a traditional trans 262 
analysis.  In addition, these direct associations fail to provide evidence for the 263 signal in either Adipose or LCLs.  264  265 
Figure 4 shows significant associations for a cluster of SNPs near LSM11 on 266 chromosome 5q33.3 which is known to be involved in histone RNA processing25 267 (see also Supplementary Figure 24). The gene loadings of our component show 268 a striking cluster of 23 histone genes in the chromosome 6p21 cluster as well as 269 the gene HIST2H2BE in the 1q21 cluster (Figure 4 purple points). There are also 270 additional signals at other histone genes on chromosome 1q42 (HIST3H2A), 271 11q23 (H2AFX) and 12p12 (HIST4H4). SNP rs6882516 (p-value = 2.39×10-15, 272 MAF=0.206) is in the 3’ UTR of LSM11 and predicted to be a microRNA binding 273 site using mirSNP26. Key histone gene regulatory factors are organized in a 274 limited number of subnuclear foci. It is known that cell cycle-dependent 275 phosphorylation of p220NPAT by cyclin E/CDK2, that induces histone gene 276 transcription, occur at these intranuclear sites. p220NPAT colocalizes with both 277 (a) the histone gene clusters on chromosome 1q21 and 6p21, (b) the protein 278 subunit LSM1113. A set of 31 significant genes (loadings with a PIP>0.5, see 279 
Online Methods) show Gene Ontology p-values of 1.91×10-25 and 1.40×10-24 for 280 the terms ‘nucleosome organization’ and ‘chromatin assembly or disassembly’ 281 respectively. The tissue scores indicate that this component is only active in 282 LCLs. Supplementary Table 4 details the direct associations of SNP rs6882516 283 with expression levels of LSM11 and the other genes in this component in all 284 three tissues. The SNP is significantly associated with LSM11 in LCLs (p-value = 285 5.57×10-33), and has p-values in the range (2.65×10-12, 1.17×10-12) with three 286 histone genes in our component with extreme gene loadings (HIST1H1C, 287 
HIST1H2BJ and HIST1H2BK). Although these associations are encouraging, they 288 do not pass a strict trans analysis significance level and additionally, these direct 289 associations do not uncover the link between LSM11 and the histone gene cluster 290 on 1q21 (the p-value for rs6882516 and HIST2H2BE in LCLs is 5.40×10-9).  291 
 292 
Figure 5 shows significant associations near the gene USP18 (see also 293 
Supplementary Figure 25). The lead SNP rs2401506 (p-value = 9.82×10-16, 294 
MAF=0.358) is 5kb upstream of USP18. The set of 160 genes in the loadings with 295 a PIP>0.5 show Gene Ontology p-values of 1.73×10-42 and 1.23×10-38 for the 296 terms ‘defense response to virus’ and ‘response to type I interferon’ respectively. 297 Of the 70 genes annotated by ‘response to type I interferon’ we find 28 with non-298 zero gene loadings (Supplementary Figure 26). These include all four of the 2'-299 5' oligoadenylate synthetase (OAS) gene family (OAS1, OAS2, OAS3 and OASL) 300 known to be actively induced by interferons27,  the genes STAT1 and STAT2 301 which are key mediators of type I and type III IFN signaling, several Interferon γ-302 inducible protein (IFI) genes (IFI6, IFI44L, IFI16, IFIH1, IFIT1, IFIT3, IFIT5, IFIT2, 303 
IFITM1, IFITM2, IFI35) and the genes MX1 and MX2 also related to IFN signaling. 304 
USP18, a type I IFN-induced protein that deconjugates the ubiquitin-like modifier 305 
ISG15 (which is also in our component) from target proteins28, plays an 306 important function in down regulation of interferon responses29,30 and 307 significantly inhibits tumour growth31. The tissue scores indicate that this 308 component is only active in LCLs. Supplementary Table 5 details the direct 309 associations of SNP rs2401506 with the 160 genes identified in this component 310 across all three tissues. There is only evidence of association in LCLs, with 311 several genes obtaining p-values smaller than 1×10-8 (IFIT1, PLSCR1, STAT1, 312 
CMPK2, RSAD2  and EIF2AK2) but none are significant when accounting for 313 genome-wide testing across all genes, suggesting that this network of genes 314 would not have been uncovered by a scan of all SNPs versus all genes. 315  316 
Figure 6 shows two significant associations on separate chromosomes for a 317 component with a striking cluster of non-zero gene loadings for zinc finger genes 318 on chromosome 19. SNP rs17611866 (p-value = 5.40×10-21, MAF = 0.251) on 319 chromosome 16 is a mis-sense variant in ZNF75A, which is one of 6 ZNF genes in 320 a local cluster. Flanking genes ZNF263 and TIGD7 have non-zero gene loadings 321 (see Supplementary Figure 27). SNP rs12630796 (p-value = 5.10×10-17, MAF = 322 0.487) on chromosome 3 is an intronic SNP in SENP7. A SNP in high LD with this 323 SNP (rs13320918, p-value = 7.34×1015, MAF = 0.377) has been shown to be a 324 microRNA QTL for miR-1270 (p-value=1.71×10-10) which is located in a zinc 325 finger cluster on chromosome 19p1232. In a separate study, 4 other intronic 326 SNPs in SENP7 (rs2553419, rs2682386, rs9859077 and rs2141180), all in high 327 
LD with each other and with rs13320918, were shown to correlate with cis-328 acting regulation of SENP7 expression in CD4 and CD8 lymphocytes and trans-329 acting regulation of ZNF154, ZNF274 and ZNF81433, which all reside within a 330 ~250-kb region on chromosome 19q13.43 (see Supplementary Figure 28).  331 
 332 
Supplementary Table 6 details the direct associations of SNPs rs12630796 and 333 rs17611866 with SENP7 on chromosome 3 and genes with non-zero gene 334 loadings in the component in all three tissues. This analysis partially recovers 335 the signal that we find using our method, see the Supplementary Note for more 336 details. 337   338 It can be challenging to interpret the large number of components that are 339 produced by sparse matrix and tensor decomposition methods. By clustering 340 components across independent runs of the method, and then selecting 341 components with genetic associations, we have shown that it is possible to 342 identify gene networks with clear biological significance. However, we have 343 found evidence that the components without genetic associations are also 344 capturing important variance in the data. Many components have individual 345 scores vectors that are significantly associated with variables measuring 346 properties of the sequencing; these components are mostly dense with several 347 thousand non-zero gene loadings (see Supplementary Figures 29-31 and 348 
Supplementary Table 7). Similarly, we have identified several components that 349 are significantly associated with measured phenotypes including age, BMI and 350 cholesterol levels (Supplementary Figure 32). We find two components that 351 show association with age. These components are shown in Supplementary 352 
Figures 33 and 34. The most significant molecular function ontology term for 353 both components is ‘oxidoreductase activity’ with p-values of 1.9×10-24 and 354 2.1×10-22.  355  356   357 In addition, we have found that it can be useful to examine the components from 358 a single run of the method. Specifically, we focus on the best run of 10 that 359 produces the highest value of the model negative free energy (Online Methods). 360 
We identified all components highlighted in Figures 2-6 with significant or very 361 close to significant GWAS p-values. In addition, we find several components that 362 identify KLF14 as a master trans regulator34 (for example, see Supplementary 363 
Figure 35). More details are given in the Supplementary Note and the 364 
Supplementary Data Set. 365  366 A previous analysis of a similar set of samples in the MuTHER study7 using a 367 microarray based gene expression experiment called 518, 491 and 493 trans 368 eQTLs SNPs at a normal GWAS threshold of 5×10-8. They reported an FDR of < 369 10% at this threshold, however only ~5% of these signals replicated at a 370 nominal significance threshold of 0.05 in at least one out of 5 other studies. The 371 overlap with our results is (a) a SNP rs7714390 on chromosome 5 (near our lead 372 SNP rs6882516) associated with two Histone genes (HIST1H2BK on chr 6 with a 373 p-value = 8×10-9 in LCLs and HIST2H2BE on chr1 with a p-value of 3.2×10-8 in 374 LCLs) (b) a SNP rs220377 on chr 16 (near our lead SNP rs17611866) associated 375 with a Zinc finger gene (ZNF667 on chr 19 with a p-value = 2.9×10-9 in LCLs), and 376 (c) several associated SNPs near rs4731702 that overlap with the KLF14 377 network with p-values between 4.4×10-8 and 2.2×10-15). This analysis did not 378 identify the Type I Interferon network or the MHC networks that we find in our 379 analysis.  380  381  382 
Discussion 383  384 We have described a new algorithm for efficient tensor decomposition for multi-385 tissue gene expression datasets, and have demonstrated its utility on a real, three 386 tissue dataset to uncover sparse gene networks with clear biological and 387 statistical significance. A marginal analysis of all SNPs versus all genes would not 388 have uncovered these networks in the same way or with as much power. For 389 example, no aspect of the Type I interferon component would have been 390 identified. We have further shown in simulations that our method has good 391 power to detect sparse gene networks correlated to genetic variants, and dense 392 confounding factors. 393 
This approach complements current eQTL analysis pipelines that tend to mainly 394 focus on identifying cis eQTLs in one tissue at a time. Analysis of cross tissue 395 effects usually proceeds in a subsequent step by comparing effect sizes across 396 tissues. Our method focuses on decomposing the complete multi-tissue dataset 397 into components of variance with varying levels of sparsity. We then test each 398 component against genetic variation genome-wide to uncover underlying eQTL 399 effects, ensuring robustness by only considering components that are 400 consistently found across multiple runs. We view our approach as 401 complementary to an association analysis of all SNPs versus all genes, since it 402 requires 2 orders of magnitude fewer tests, and has more power to detect SNP 403 associations with gene networks. 404  405 In general, we find that dense components uncovered by our method show high 406 levels of significance with confounding variables and the method additionally 407 uncovers many very sparse components that represent cis eQTLs. More 408 interestingly, we find 6 components with intermediate levels of sparsity with 409 gene loadings spread across multiple chromosomes that represent gene 410 networks showing a highly significant association with genetic variants. In all 6 411 of these components, we are able to link the gene networks they describe to 412 known biology. In the future it will be natural to apply this method to gene 413 expression datasets with even more tissues, such as that being collected by the 414 GTEx Project37 or the Allen Institute for Brain Science (AIBS) human microarray 415 data set38. 416  417 There are several interesting ways in which this model can be extended or 418 changed. The method can be naturally extended to higher dimensional datasets. 419 For example, 4D multi-tissue gene expression experiments through time and/or 420 under different experimental conditions (see Supplementary Figure 36). 421  422 One assumption of our model is that the gene loadings pattern of a component is 423 constant across active tissues, which may or may not be true dependent upon the 424 dataset being analyzed. One way to overcome this would be to develop a model 425 that applies a matrix decomposition to the gene expression matrix for each 426 
tissue but with a linked individual scores matrix (see Supplementary Figure 427 
37). A downside of such an approach is that it would significantly increase the 428 number of unknown parameters in the factorization. However, this model would 429 allow variation in the gene loadings between tissues if there were indeed clear 430 differences, and might be a way of combining together components found by our 431 tensor method (like those describing MHC class II regulation pathways) with 432 clearly similar gene loadings. However, it may also be necessary to model the 433 similarity between gene loadings to aid estimation, given the larger parameter 434 space. This approach has strong connections to sparse canonical correlations 435 analysis (CCA)39 and unsupervised multi-view learning40. 436  437  438 Such a linked matrix decomposition method could also be used to integrate 439 different genomic datasets. The model has no constraint that the set of matrices 440 being jointly decomposed have the same dimensions. So, for example, matrices of 441 gene expression and epigenetic measurements could be jointly decomposed to 442 uncover relevant shared biology (see Figure 7). Example applications might 443 include joint decomposition of different omics datasets collected on cancer 444 samples from the International Cancer Genome Consortium (ICGC) (see URLs). 445 This model can further be extended to tensors of different data types (see 446 
Supplementary Figure 38).     447 
 448 
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 578  579  580 
Figure Legends 581 
 582 
Figure 1 : Graphical representation of the method. The gene expression data 583 tensor (top left) is decomposed into the product of an individual scores matrix, a 584 tissue scores matrix and a gene loadings matrix (top right). Columns of the 585 individual scores matrix are then used as phenotypes in a GWAS using SNP 586 genotypes (bottom left) in order to uncover genetic variation correlated with the 587 latent components. 588  589 
Figure 2 : MHC Class II regulation. Figures a and b shows two components 590 identifying a similar network in different tissues. (Top left) GWAS with the 591 component’s individual scores vector as a phenotype. (Top right) Boxplot of 592 individual scores stratified by genotypes at the lead GWAS SNP. Boxplots show 593 the median, upper and lower quartiles, with whiskers extending to either 1.5 594 times the interquartile range (IQR), or to the most extreme data point if this is 595 within 1.5 times IQR. (Bottom left) Gene loadings for the component. Only gene 596 loadings with a PIP>0.5 are shown. (Bottom right) Tissue scores vector for the 597 component shown as a barplot. 598 
Figure 3 : MHC Class I regulation. (Top left) GWAS with the component’s 599 individual scores vector as a phenotype. (Top right) Boxplot of individual scores 600 stratified by genotypes at the lead GWAS SNP rs289749. (Bottom left) Gene 601 loadings for the component. Only gene loadings with a PIP>0.5 are shown. 602 (Bottom right) Tissue scores vector for the component shown as a barplot.  603 
Figure 4 : Histone RNA processing. (Top left) GWAS with the component’s 604 individual scores vector as a phenotype. (Top right) Boxplot of individual scores 605 stratified by genotypes at the lead GWAS SNP rs6882616. (Bottom left) Gene 606 loadings for the component. Only gene loadings with a PIP>0.5 are shown. 607 (Bottom right) Tissue scores vector for the component shown as a barplot.  608 
Figure 5 : Type I Interferon Response. (Top left) GWAS with the component’s 609 individual scores vector as a phenotype. (Top right) Boxplot of individual scores 610 stratified by genotypes at the lead GWAS SNP rs2401506. (Bottom left) Gene 611 loadings for the component. Only gene loadings with a PIP>0.5 are shown. 612 (Bottom right) Tissue scores vector for the component shown as a barplot. 613 
Figure 6 : Zinc finger gene network. (Top left) GWAS with the component’s 614 individual scores vector as a phenotype. (Top right) Boxplots of individual scores 615 stratified by genotypes at the lead GWAS SNPs, rs17611866 and rs12630796. 616 (Bottom left) Gene loadings for the component, with zinc finger genes on chr 19 617 highlighted in purple. Only gene loadings with a PIP>0.5 are shown. (Bottom 618 right) Tissue scores vector for the component shown as a barplot.  619 
Figure 7 : Multi-omics data integration. Graphical representation of a linked 620 decomposition for several genomic assays. A matrix decomposition is applied to 621 each data type. The matrix decompositions identify a different loadings matrix 622 for each data type and a shared individual scores matrix.  623 
 624  625 
Online methods 626  627 Bayesian Sparse Tensor Decomposition Model 628 We use Y to denote the 3D array or tensor containing pre-processed gene 629 expression measurements. Y has dimensions × ×  where N is the number of 630 individuals, L is the number of genes and T is the number of tissues. We model Y 631 as follows 632  Ynlt = AncBtc Xcl + εnlt
c=1
C
   633 where C is the number of components (also called factors). A is an ×  matrix 634 with the cth column containing the individuals scores of the cth component.  B is a  635 ×  matrix with the cth column containing the tissue scores of the cth 636 component.  X is a ×  matrix with the cth row containing the gene loadings of 637 the cth component. 638  639 The error term is modeled as εnlt ~ N 0,λlt−1( ) where λlt  is the precision of the 640 error term at the lth gene in the tth tissue.  641  642 We deal with missing samples for a given tissue by not including them in the 643 model likelihood. We introduce an indicator variable Int  that equals 1 when gene 644 expression has been measured in tissue t for sample n and zero otherwise. The 645 likelihood is then given by 646  P Y Θ( ) = P Ynlt Θ( )Int
n ,l ,t∏   647 where Θ  is the vector of model parameters. 648  649 
We fit this model in a Bayesian framework, and place priors on the entries of the 650 matrices A, B, X and also the precisions λlt . A key prior is the one we place on the 651 elements of the gene loadings matrix X. We wish to encourage sparsity in the 652 rows of this matrix, so we use a hierarchical ‘spike and slab’ prior42 of the form 653 
 
Xcl ~ pclN 0,βc−1( )+ 1− pcl( )δ0
βc ~Gamma e, f( )
pcl ~ ρcBeta q,r( )+ 1− ρc( )δ0
ρc ~ Beta s ,z( )
  654 
For the purposes of making inference easier (see Supplementary  Note) we use 655 the equivalent factorization of the spike and slab distribution as Xcl = WclScl  656 where 657 
 Wcl ~ N 0,βc−1( )
Scl ~ Bernoulli pcl( )  658 For the elements of A and B we use standard normal priors Anc ~ N 0,1( )  and 659  Btc ~ N 0,1( ) .  660 
 661 Model fitting 662  663 We fit this model using Variational Bayes (VB)43, which approximates the 664 posterior distribution P Θ Y( ) ≈ Q Θ( ) . The approach iteratively refines the 665 estimate  Q Θ( ), by minimizing the Kullbeck-Lieber (KL) divergence between 666 
 
Q θ( )  and P Y θ( ) , or equivalently maximize the negative free energy. Once 667 converged,  Q θ( )  can be used to approximate properties of the posterior 668 distribution. The full details of the parameter factorization we use, the resulting 669 VB update equations and details of parameter initialization are given in the 670 
Supplementary Note. The resulting algorithm has complexity O NLTC2( ) and 671 can be run on a multi-core server. For the TwinsUK data analyzed in this paper 672 the method took 20 hours for each of the 10 runs using 8 threads.  673 
 674 Our model has the ability to shrink an entire component to zero ( = 0) and 675 effectively remove that component from the model. In this way our model can 676 adaptively choose the number of components it needs. Just a small amount of 677 experimentation is needed to find a large enough value of C so that components 678 start being shrunk to 0. For the TwinsUK data we fit the model with 1,000 679 components and found that in all 10 runs of the method around 50 components 680 would always be estimated as 0. 681 Summarizing the Variational Bayesian posterior approximation 682  683 The form of the VB posterior for every entry of the gene loadings matrix Xcl  has 684 the same spike and slab form as the prior. We use this distribution to calculate 685 the expected value, denoted EQ Xcl( ) . We also calculate a Posterior Inclusion 686 Probability (PIP) that Xcl  is not equal to zero, which is equal to EQ Scl( ) . We use 687 the PIPs to infer a network of genes for each component consisting of the genes 688 with a PIP > 0.5.  We summarize the individual and tissue scores vectors in a 689 similar way by using the expected values of the VB posterior,  EQ Acl( )  and 690 
 
EQ Bcl( )  respectively. 691 
 692 Identifying robust components 693  694 The model is complex and has a large number of parameters and there is no 695 guarantee that the VB algorithm will find a global solution when optimizing the 696 bound on the marginal likelihood. Running the method multiple times highlights 697 this issue. Some components are found consistently across multiple runs, 698 whereas other components only occur in a small number of runs. For example, 699 our method often uncovers components that show strong cis eQTL signals when 700 using the associated component scores as phenotypes. To identify robust 701 components, we implemented a method that clusters similar components across 702 different runs. We then focus on large clusters containing components from 703 
multiple different runs, and use these as the basis for our search for novel 704 signals.  705  706 More specifically, we run our method 10 times and store the individual and 707 tissue scores, gene loadings and PIPs. We calculate the absolute correlation 708 between the individual scores for all pairs of components across the 10 runs. 709 Hierarchical clustering is then used to group components into clusters, using one 710 minus the absolute correlation as a dissimilarity measure. The clustering is 711 terminated when no correlations between clusters are above 0.6.  712  713 The components within each cluster are then combined. We take the mean of the 714 individual scores, tissue scores and gene loadings and the median PIPs. The 715 individual scores for each component cluster are then used as a phenotype 716 against a genome-wide dataset of SNPs on the same individuals to identify which 717 components have a genetic basis. We apply quantile normalization to the 718 individual scores before testing for association with SNPs. Tissue scores are 719 thresholded to obtain tissue activity patterns. The distribution of tissue scores 720 tends to be tri-modal with one, well defined mode centered on zero so a 721 threshold can easily be picked to set small score values to zero.  We only test 722 averaged components calculated from clusters with a minimum (user-defined) 723 membership size, in order to focus on components that are robustly and 724 consistently identified across runs.  725  726 Analysis of the TwinsUK dataset 727  728 Gene expression levels were measured for 845 female twins from the TwinsUK 729 cohort using whole transcriptome sequencing (RNA-seq), with data in three 730 tissues (adipose, lymphoblastoid cell lines (LCLs) and skin) for the majority of 731 the individuals19,20. Experiments were performed using the Illumina TruSeq 732 sample preparation kit and sequenced on a HiSeq2000 machine. Reads were 733 mapped on to the GRCh37 reference genome using BWA v0.5.944. Only reads that 734 map uniquely were used. We run the method using RPKMs (reads per kilobase 735 per million) after performing the following pre-processing and normalization 736 
steps; (i) genes with >20% zeros in all three tissues are removed resulting in 737 18,409 genes, (ii) quantile normalization of expression data within each tissue, 738 (iii) rank based transformation of each gene onto a standard normal.  739  740 Samples were genotyped on a combination of the HumanHap300, 741 HumanHap610Q, 1M-Duo and 1.2MDuo Illumina arrays. Samples were imputed 742 using the 1000 Genomes Project Phase 1 reference panel (data freeze 10 743 November 2010) using IMPUTE245 and filtered (minor allele frequency (MAF) < 744 0.01 and IMPUTE info value < 0.8). Imputed genotypes were available on 795 of 745 the 845 individuals. 746 We also used 11 concurrently measured phenotypes that were available on the 747 samples (age, BMI, weight, height, total cholesterol, HDL cholesterol, LDL 748 cholesterol (calc), total triglycerides, adiponectin, insulin and glucose) and 749 variables derived from the sequencing. Specifically, we used (a) the mode of the 750 insert size calculated for each sample, which can vary between sequencing 751 library preps, (b) GC-content of the reads from a sample, which can vary due to 752 biochemical differences in library prep and lane effect, (c) date of sequencing 753 and (d) primer index. 754  755 We ran our method 10 times on the dataset and combined components across 756 runs via clustering (see above).  Supplementary Figure 39 shows the resulting 757 distribution of cluster size. Only those clusters with more than or equal to 5 758 components were then retained for GWAS.  759  760 We used a linear mixed model46 to test an individual scores vector as a 761 phenotype against the SNP genotypes. The scores vector was subset down to the 762 795 individuals for which imputed genotype data was available. We used a 763 Bonferroni corrected significance threshold of 1×10-10, calculated by scaling a 764 genome-wide significance threshold of 5×10-8 by 500 to account for the multiple 765 GWAS we perform. 766  767 
Testing associations between individual scores vectors and phenotypes and 768 batch variables was also performed using a linear mixed model46, again only 769 using 795 individuals. Only one member of each twin pair was used in the 770 associations with age. The categorical batch variables, date and primer index, 771 were dealt with by creating binary vectors (one for each category) and 772 individually using these as a fixed effect in the linear mixed model. 773  774 Gene Ontology analysis was carried out using the TopGO R package47. Gene 775 ontology analysis evaluates whether a particular set of genes are enriched for a 776 GO term in comparison to a background gene set. TopGO uses Fisher's exact test 777 to get a p-value for enrichment based on the expected and observed number of 778 genes with a GO term. Of the 18,409 genes used in this analysis, 13,965 have GO 779 annotations.  To get a significance level for this analysis we randomly sampled 780 10,000 sets of genes of a random size and performed an enrichment analysis on 781 each set. We take the smallest p-value from each gene set to create a null 782 distribution and use this distribution to estimate a significant level of 1%.  783  784 We use a linear mixed model46 to perform direct associations between the SNPs 785 and the (normalized) expression levels of genes involved our components. In 786 order to account for unmeasured confounding factors, we fit the PEER model23 to 787 each tissue’s expression data with 15 factors and use these as covariates in the 788 mixed model. In addition to the PEER factors, we also include two phenotypes, 789 (age and BMI) and two tissue-specific batch variables (GC mean and insert size 790 mode) as covariates.  791  792 Application of fastICA 793 We used the R package fastICA to apply ICA to the TwinsUK dataset. We 794 concatenated the normalized expression data from the 3 tissues into a single 795 matrix. Only 618 out of 845 individuals had expression data on all 3 tissues, so 796 this matrix had 618 rows and 3×18409 columns. We fit the maximum number of 797 components possible (618). We selected the 200 components for the measure of 798 kurtosis of the gene loadings was > 3.5 and ran a GWAS against all SNPs. We also 799 tested the components individual scores against the known confounding 800 
variables from the sequencing. More details are given in the Supplementary 801 
Note. 802  803 42. Lucas, J. et al. in Bayesian Inference for Gene Expression and Proteomics 804 (eds. Do, K.-A., Muller, P. & Vannucci, M.) 1–25 (2006). 805 43. Jordan, M. I., Ghahramani, Z. & al, E. An introduction to variational methods 806 for graphical models. in 183–233 (MIT Press, 1999). 807 44. Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows-808 Wheeler transform. Bioinformatics 25, 1754–1760 (2009). 809 45. Howie, B., Marchini, J. & Stephens, M. Genotype imputation with thousands 810 of genomes. G3 (Bethesda) 1, 457–470 (2011). 811 46. Zhou, X. & Stephens, M. Genome-wide efficient mixed-model analysis for 812 association studies. Nat. Genet. 44, 821–824 (2012). 813 47. Alexa, A. & Rahnenfuhrer, J. topGO: enrichment analysis for gene ontology. 814 (R package version, 2010). 815  816 
Tissues
Gene$expression$data
Genotype$data
= 
SNPs
Genes
In
di
vi
du
al
s
In
di
vi
du
al
s
Genes
●
●
●●
●
●
●
●
●
●
●●
●●
●
●
●
●
●
●
●●
●●
●
●
●
●
●
●●●●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●●●
●●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●●
●
●
●
●
●●
●●
●
●
●●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●●
●
●
●●
●
●
●
●●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●●
●
●●●●
●
●
●●
●
●●
●
●
●
●●●
●
●●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●●
●●
●●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●●
●
●●
●
●
●
●
●●
●
●
●
●
●
●
●
●●
●
●
●●
●
●●●
●
●
●
●●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●●
●●
●
●●
●
●●
●
●
●
●
●
●
●
●
●●●
●
●●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●●
●●
●●
●
●
●
●
●
●●
●●
●
●
●●
●
●
●
●
●
●●
●
●
●
●●
●
●●
●
●
●
●
●
●
●
●●●
●
●●
●
●●●
●
●
●
●
●
●
●
●
●
●●
●
●
●●●
●●
●
●
●
●
●
●
●
●
●●
●
●
●
●●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●●
●●
●●
●●
●
●
●
●
●
●●●
●
●
●
●●
●●
●
●
●●
●
●
●
●●
●
●
●
●
●
●
●
●
●●
●
●
●●
●
●●
●
●●
●●
●
●
●
●
●●
●
●
●●●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●●
●●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●●
●
●
●
●
●●
●
●
●
●●
●
●
●●
●
●
●●
●
●
●●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●●●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●●
●●
●●
●
●
●●
●
●
●●●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●●
●
●●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●●
●●
●
●
●●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●●
●
●●
●●
●●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●●●
●
●●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●●
●●
●
●
●
●
●
●
●●
●●
●
●
●
●
●
●●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●●
●
●
●●
●●●
●
●
●
●
●
●
●
●●
●●
●
●
●
●●
●
●●
●
●
●●
●
●
●
●
●
●
●
●●●
●
●●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●●
●●
●
●
●
●
●
●●
●
●
●
●●
●●
●
●
●
●●
●
●
●
●●
●●
●
●
●
●
●●
●●
●●
●●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●●
●
●
●
●●
●
●
●
●●
●
●
●
●
●
●
●
●●
●
●●
●
●
●●
●
●
●
●
●
●
●
●
●●
●
●
●
●●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●●●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●●●
●
●
●
●
●
●
●●
●
●
●
●●
●
●
●
●
●
●●●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●●
●●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●●
●
●
●
●●
●
●●
●●●●●
●
●
●
●
●
●
●●
●●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●●
●
●●
●
●
●
●
●
●
●●●
●
●
●
Tissue$scores$matrix
Individual$scores$matrix
In
di
vi
du
al
s
Components
Sparse$gene$loadings$matrix
Co
m
po
ne
nt
s
Components
Tissues





= ×
L1
In
di
vi
du
al
s
Individual(scores(matrix
In
di
vi
du
al
s
Components
Sparse(loadings(matrices
L1
Co
m
po
ne
nt
s
Omics type(2
In
di
vi
du
al
s
Omics type(1
Omics type(3(
In
di
vi
du
al
s
L3
Co
m
po
ne
nt
s
L2
Co
m
po
ne
nt
s L3
L2
